Preventing Deoxygenation With High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery: A Randomized Controlled Trial
Sponsor study identifier
interventional
60
1 country
1
Study Start
August 1, 2020
Actual (reported)Primary Completion
November 10, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
High-flow nasal cannula (HFNC) is a device that delivers10 to 70 L min-1 of heated, humidified 100% oxygen via nasal route. It provides positive airway pressure, decreases dyspnea, decreases the work of breathing, and improves comfort
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1, 2020
Actual (reported)August 16, 2020
Actual (reported)August 20, 2020
Actual (reported)November 10, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 1, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
arterial partial pressures of oxygen
an arterial blood sample will be taken after induction of anaesthesia then every 10 min till the end of the operation.
two hours
pH measurement
an arterial blood sample will be taken after induction of anaesthesia then every 10 min till the end of the operation.
two hours
For HFNC group, F\&P AIRVOTM 2 will be adjusted to give the patients the oxygen flow at 50L/min and the FiO2 at 1.0.Then after three minutes of preoxygenation, sedation will be conducted by giving 25 µg fentanyl and a bolus of 1 mg/kg propofol followed by continuous infusion of propofol using a target-controlled infusion system (TCI pump TE371; Terumo Corporation, TokyoJapan).
induction of general anaesthesia will be done using 2 mg/kg propofol and 1 µg/kg fentanyl. Double lumen tube will be facilitated by cisatracurium 0.2 mg/kg. Anaesthesia will be maintained with isoflurane 0.8 %-1% in 100% oxygen and maintenance dose of cisatracurium 0.02 mg/kg when needed. At the end of surgery, residual neuromuscular paralysis will be antagonized with neostigmine 0.05 mg/kg and atropine 0.01 mg/kg.
using sedation with the HFNC F\&P AIRVOTM 2 to maintain oxygenation
using general anaesthesia with one lung ventilation (OLV) technique
Rehab Abd Elraof Abd Elaziz
Alexandria, 000000, Egypt
Rehab A. Abd Elaziz, Ass.Prof.
Alexandria University
First Submitted
August 16, 2020
First Posted
August 20, 2020
Study Start
August 1, 2020
Actual (reported)Primary Completion
November 10, 2020
Estimated (date passed)Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 20, 2020
Record last verified: 2020-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: